Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards
Microbiology Spectrum · 03.11.2026 · 14 (11)
DOI: 10.1128/spectrum.02235-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Stefano Mancini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology, University of Zurich, Zürich, Switzerland. Hauptthemen laut MEDLINE: beta-Lactamases, Pseudomonas aeruginosa, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pseudomonas aeruginosa can develop carbapenem resistance through chromosomal mechanisms and/or by acquiring plasmid-mediated carbapenemases, including the most prevalent metallo-β-lactamases (MBLs) and/or extended-spectrum β-lactamases (ESBLs). Conventional β-lactam susceptibility testing does not reliably discriminate MBL/ESBL-producing carbapenem-resistant P. aeruginosa (MBL/ESBL-CRPA) from non-carbapenemase-producing isolates, here referred to as AmpC-hyperproducers. However, these groups exhibit distinct susceptibility patterns to novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations, including ceftolozane/tazobactam (C/T), ceftazidime/avibactam (C/A), imipenem/relebactam (I/R), and meropenem/vaborbactam (M/V). We investigated potential screening cut-offs for detecting MBL/ESBL production in CRPA using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. Antimicrobial susceptibility testing was performed using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards on 135 whole-genome-sequenced international CRPA isolates resistant by disc diffusion to ceftazidime, cefepime, imipenem, and/or meropenem. The collection included 71 MBL-producing isolates, of which nine co-produced ESBLs, as well as one KPC-2-, one GES-5-, and twelve ESBL-only producers. The remaining 50 represented AmpC-hyperproducers. MIC distributions were analyzed to identify discriminatory screening cut-offs. C/T was the most discriminatory BL/BLI combination for differentiating MBL/ESBL-CRPA from AmpC-hyperproducers. For the VITEK-2 AST-N443, a C/T MIC ≥32 mg/L achieved 100% sensitivity for MBL±ESBL detection (71/71) and 91.7% sensitivity for ESBL-only producers (11/12), with 82% specificity (41/50). For the Phoenix NMIC-486, a C/T MIC >8 mg/L achieved 100% sensitivity for both MBL and ESBL detection, with 80% specificity (40/50). Combining additional BL/BLI agents did not further improve specificity. Elevated C/T MICs represent reliable phenotypic screening markers for MBL and ESBL production in CRPA using both the VITEK-2 AST-N443 and Phoenix NMIC-486 systems. IMPORTANCE Rapid identification of the underlying resistance mechanism in carbapenem-resistant Pseudomonas aeruginosa (CRPA) is essential for effective treatment and infection control. Differentiating high-level resistance acquired via plasmid-borne carbapenemases and/or extended-spectrum β-lactamases (ESBLs) from resistance driven by intrinsic mechanisms, including AmpC-type β-lactamase hyperproduction, remains challenging because conventional antimicrobial susceptibility testing (AST) using classic β-lactams cannot reliably separate these phenotypes. This distinction is relevant because many recently introduced β-lactam/β-lactamase inhibitor combinations are inactive against metallo-β-lactamase (MBL) carbapenemase-producing isolates but may remain active against strains in which resistance is driven by intrinsic mechanisms. Detection of acquired carbapenemases may also trigger enhanced infection-control measures and epidemiological investigations. Our study identifies reliable screening cut-offs for MBL- and ESBL-production in CRPA using standard VITEK 2 and Phoenix automated AST panels. This readily available approach may accelerate detection, support routine laboratory workflows, reduce unnecessary confirmatory testing, and facilitate earlier targeted therapy and infection-control interventions in laboratories using these systems worldwide without requiring additional specialized testing or infrastructure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Microbiology, University of Zurich, Zürich, Switzerland.
- Istituto di Medicina di Laboratorio EOC, Bellinzona, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University of Zurich, University Hospital Zurich, Zürich, Switzerland.
- Department of Laboratory Medicine, Clinical Bacteriology/Mycology, University of Basel, Basel, Switzerland.
- Department of Microbiology, The University of Haripur, Haripur, Pakistan.
ORCID-Profile: Stefano Mancini, Silvio D Brugger, Helena M B Seth-Smith, Peter M Keller, Tim Roloff, Oliver Nolte
Zitieren
APA
Mancini, S., Mueller, L., Brugger, S. D., Seth-Smith, H. M. B., Keller, P. M., Kolesnik-Goldmann, N., Syed, M. A., Roloff, T., & Nolte, O. (2026). Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.02235-26
Vancouver
Mancini S, Mueller L, Brugger SD, Seth-Smith HMB, Keller PM, Kolesnik-Goldmann N, et al. Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.02235-26
BibTeX
@article{Mancini2026,
author = {Mancini, Stefano and Mueller, Linda and Brugger, Silvio D and Seth-Smith, Helena M B and Keller, Peter M and Kolesnik-Goldmann, Natalia and Syed, Muhammad Ali and Roloff, Tim and Nolte, Oliver},
title = {Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards},
journal = {Microbiology Spectrum},
year = {2026},
volume = {14},
number = {11},
doi = {10.1128/spectrum.02235-26}
}
EUVIMED